Research
Hormonal
Semaglutide, a GLP-1 receptor agonist, produces significant weight loss (up to 15.8% at 68 weeks) and improves cardiovascular outcomes in patients with obesity or type 2 diabetes.
Semaglutide is a highly effective weekly injection for obesity and type 2 diabetes, achieving nearly 15% weight loss in clinical trials. It works by mimicking the GLP-1 hormone, which regulates hunger and digestion. It also offers cardiovascular benefits, reducing the risk of heart attack and stroke.
StrongSupportsHIGH confidence
The STEP 1 randomized controlled trial investigated semaglutide 2.4 mg weekly and found a body weight loss of −14.9% vs −2.4% with placebo at 68 weeks.
Why this rating
Supported by Phase 3 trials (STEP 1-5, SELECT).
Source
Pharmacotherapy for Obesity: Recent Updates
Thomas W. Fredrick et al. · Clinical Pharmacology Advances and Applications · 2025
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →